ArticleThe Lancet. Infectious diseases2020
Convalescent plasma as a potential therapy for COVID-19.
14 registry-linked trialsAbstract readComment
In one paragraph
Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 14 registered trials, which are not on this map. Cited by 536 papers, 11 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
536citing papers in PubMed, 11 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
Randomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients
Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection
Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety
Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients
Who cites it
536 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.The Cochrane database of systematic reviews · 2022Pooled it
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021Pooled it
- Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.Journal of clinical apheresis · 2021Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.Journal of medical virology · 2021Pooled it
- Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.European journal of internal medicine · 2022Trial
- Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.JCI insight · 2022Trial
- Trial
- Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.Journal of internal medicine · 2021Trial
- Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.International immunopharmacology · 2021Trial
- SARS-CoV-2 RNA-binding protein suppresses extracellular miRNA release.RNA biology · 2025Article
- Proteomic and metabolomic profiling of plasma reveals physiologic changes in patients with convalescent COVID-19.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Article
- Effectiveness of dolutegravir in moderate severity COVID-19 patients: A single-center, randomized, double-blind, placebo-controlled trial.BioImpacts : BI · 2025Article
476 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
4 authors.
Long ChenDepartment of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.
Jing XiongDepartment of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.
Lei BaoDepartment of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.
Yuan ShiDepartment of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China. Electronic address: petshi530@vip.163.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveImmunoglobulinsPandemicsPneumonia, ViralSARS-CoV-2Immunoglobulins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04321421ClinicalTrials.gov
NCT04355247ClinicalTrials.gov
NCT04360356ClinicalTrials.gov
NCT04361318ClinicalTrials.gov
NCT04383548ClinicalTrials.gov
NCT04385043ClinicalTrials.gov
and 8 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.